Polivy (polatuzumab vedotin-piiq) / Roche, Pfizer - LARVOL DELTA

ARV-393, a PROTAC B-cell lymphoma 6 (BCL6) degrader, combined with biologics or small molecule inhibitors (SMIs) induces tumor regressions in diffuse large B-cell lymphoma (DLBCL) models (AACR 2025) - P1 | "For example, CREBBP/EP300 and BCL6 have opposing transcriptional activities and BCL6 degradation may prevent CD20 downregulation by restoring CREBBP/EP300 chromatin access, supporting combination with anti-CD20 biologics; cooperation of EZH2 with the BCL6 repressor complex supports combining with tazemetostat (taz). Thus, we assessed the activity of ARV-393 in combination with biologics or SMIs based on potential complementary mechanistic roles.ARV-393 was administered in combination with clinically relevant doses of the standard of care (SOC) biologics rituximab, tafasitamab (tafa) and polatuzumab to mice bearing SU-DHL-4 CDX, representing a high-grade B-cell lymphoma (HGBCL, with MYC, BCL2 and BCL6 rearrangements). ARV-393 was also combined with investigational SMIs of EZH2 (taz), BCL2 (venetoclax) and BTK (acalabrutinib), in HGBCL or aggressive CDX models SU-DHL-6 (EZH2mut), OCI-Ly1 (BCL2+) and activated B-cell (ABC)-like OCI-Ly10 (MYD88 mut),..."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Oncology • BCL2 • BCL6 • CREBBP • EP300 • MYC • MYD88

A Review of NICE UK Submissions for Antibody-Drug Conjugates in Oncology (ISPOR 2025) - "All of these ADCs were assessed by NICE from inception to 2024 12 FDA-approved ADCs were identified: Trastuzumab emtansine, Trastuzumab deruxtecan, Sacituzumab govitecan, Inotuzumab ozogamicin, Polatuzumab vedotin, Loncastuximab tesirine, Tisotumab vedotin, Enfortumab vedotin, Mirvetuximab soravtansine-gynx, Belantamab mafodotin-blmf, Gemtuzumab ozogamicin, and Brentuximab vedotin. In conclusion, ADCs have revolutionized cancer treatment with their targeted delivery and significant therapeutic benefits. The evolution of ADCs since 2000 highlights their potential in both refractory and early-stage diseases. Continued advancements in ADC design and technology promise even greater therapeutic efficacy."

NICE • Review • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Cell Lymphoma • Breast Cancer • Cervical Cancer • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Solid Tumor • Urothelial Cancer

Durable Efficacy With Fixed-Duration Epcoritamab + Polatuzumab, Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) For 1L DLBCL (EPCORE NHL-5) (ICML 2025) - No abstract available

Clinical • Diffuse Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Cost Opportunity of Polatuzumab Vedotin as First-Line Therapy for DLBCL on Subsequent Treatments - Brazilian Cost Analysis (ISPOR 2025) - "OBJECTIVES: To analyze the direct cost of treating Diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin (Pola-R-CHP) as first line (1L) therapy, CAR T-cell as a second line (2L) treatment, or epcoritamab as a third line (3L) therapy. Quantitative analysis based on an expert panel discussion about the different costs that contribute to the direct medical cost of the treatments. This study demonstrates the potential to treat and cure more patients in 1L with Pola-R-CHP and provide them with a higher likelihood of avoiding progression compared to other treatments. The progression disease rate in 1L with Pola-R-CHP, is 23.3% for DLBCL patients and 16.1% for high-risk patients (ABC diagnosis), compared to 54% with CAR T-cell therapy and 72.2% with epcoritamab. This information could help decision-makers in engaging in evidence-based and value-driven discussions for patients and healthcare systems, promoting greater efficiency and transparency in terms of budget..."

Clinical • Cost-analysis • HEOR • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Combined Impact of Prior Polatuzumab Vedotin Plus Bendamustine and Rituximab Therapy and Myeloablative Conditioning on Early Post-Transplant BK Virus-Associated Hemorrhagic Cystitis. (PubMed, J Hematol) - "We analyzed the shared characteristics between these two cases to distinguish between the factors that trigger the onset of BKV-HC and those that contribute to its severity. Based on the differences in the clinical course between the two cases, we propose prevention strategies for BKV-HC and identify treatment strategies for Pola-BR in patients with R/R DLBCL undergoing allogeneic transplantation."

Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Thyroid Lymphoma Presented as a Painful Cervical Mass: a Diagnostic Dilemma (ESPE-ESE 2025) - "Treatment and Outcome: The patient was treated with six cycles of Polatuzumab, Rituximab, Cyclophosphamide, and Methylprednisolone (Pola-R-CHP) every 21 days. Although rare, thyroid lymphoma should be considered in the differential diagnosis of rapidly enlarging thyroid masses. Early recognition and timely intervention are critical for improving prognosis, particularly in cases without a prior history of Hashimoto’s thyroiditis. This case highlights the diagnostic complexity of thyroid lymphoma and the importance of comprehensive staging and tailored treatment."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Endocrine Cancer • Endocrine Disorders • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hypoparathyroidism • Lymphoma • Musculoskeletal Pain • Non-Hodgkin’s Lymphoma • Oncology • Otorhinolaryngology • Pain • Solid Tumor • Thyroid Gland Carcinoma

A Rare Case of Diffuse Large Bcell Lymphoma Diagnosed in Longstanding Symptomatic Hemorrhoids (ASCRS 2025) - "She was then transitioned after cycle 1 to R-CHP plus polatuzumab (pola-R-CHP) per POLARIX trial and completed 5 cycles 3 months later...PET/CT 3 months after chemotherapy showed stable findings and she remained asymptomatic on most recent surveillance visit.Conclusion/ While gastrointestinal involvement of lymphoma is more commonly seen, findings of malignant lymphoma in hemorrhoidal tissue is extremely rare, described only by a handful of case reports. Clinicians should be aware of how these may present, including as hemorrhoids and perianal abscesses, as well as general work up and treatment for suspected anorectal lymphoma.PET/CT scans pre- and post-chemotherapyPET/CT pre-chemotherapy (A) and post-chemotherapy (B)"

Clinical • Anesthesia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Epstein-Barr Virus Infections • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • MYC • TP53

Fixed–duration outpatient subcutaneous mosunetuzumab + polatuzumab vedotin shows robust efficacy in a Phase II study of relapsed/refractory post–BTKi mantle cell lymphoma (ICML 2025) - No abstract available

Clinical • P2 data • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology

A multicenter phase II study of glofitamab plus polatuzumab–R–CHP for patients with high–risk diffuse large B–cell lymphoma (ICML 2025) - No abstract available

Clinical • P2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

POLATUZUMAB-CONTAINING REGIMENS AS BRIDGE TO CAR-T: INSIGHTS FROM THE ITALIAN CAR T-SIE STUDY (ICML 2025) - No abstract available

Lymphoma

Polatuzumab vedotin, rituximab, gemcitabine and oxaliplatin (Pola–R–GemOx) for relapsed/refractory (R/R) diffuse large B–cell lymphoma (DLBCL): Phase III POLARGO trial (ICML 2025) - No abstract available

P3 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Polatuzumab vedotin with dose adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (PERCH) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas (ICML 2025) - No abstract available

B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Feasibility of 2nd-line CAR-T cell therapy after early failure of Polatuzumab-containing 1st-line chemoimmunotherapy in patients with diffuse large B-cell lymphoma (ICML 2025) - No abstract available

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Effectiveness and Genomic Landscape of Front-Line Polatuzumab-Based Regimens in Diffuse Large B-Cell Lymphoma: A Real-World Single-Center Study on TP53-Mutated Subgroups (ICML 2025) - No abstract available

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TP53

Efficacy and Safety of Polatuzumab Vedotin, Zanubrutinib and Rituximab (Pola-ZR) in Untreated Elderly and Frail DLBCL Patients: A Prospective Phase 2 Clinical Trial (ICML 2025) - No abstract available

Clinical • P2 data • Diffuse Large B Cell Lymphoma • Lymphoma • Oncology

Polatuzumab vedotin and glofitamab: a synergistic approach to anti-tumor activity (ICML 2025) - No abstract available

Lymphoma • Oncology

Polatuzumab vedotin-Based Combination Therapy Demonstrates Efficacy and Safety in Elderly Diffuse Large B-Cell Lymphoma Patients (ICML 2025) - No abstract available

Clinical • Combination therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Polatuzumab vedotin as an effective salvage therapy for relapsed/refractory mantle cell lymphoma resistantance to BTK and BCL inhibitors (ICML 2025) - No abstract available

Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology

Polatuzumab Vedotin with BTK Inhibitors and Chemotherapy Shows Rapid, Deep Responses in Non-GCB Diffuse Large B-Cell Lymphoma (ICML 2025) - No abstract available

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Treatment-related infections and clinical outcomes of Diffuse Large B-Cell Lymphoma treated with polatuzumab vedotin-based combination therapy (ICML 2025) - No abstract available

Clinical • Clinical data • Combination therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Polatuzumab vedotin improves efficacy and survival in newly diagnosed advanced diffuse large B-cell lymphoma: A multicenter retrospective analysis (ICML 2025) - No abstract available

Metastases • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma (clinicaltrials.gov) - P2 | N=8 | Active, not recruiting | Sponsor: Barbara Ann Karmanos Cancer Institute | Recruiting ➔ Active, not recruiting | N=49 ➔ 8 | Trial completion date: Nov 2026 ➔ Jun 2025 | Trial primary completion date: Nov 2025 ➔ Jun 2025

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • MYC

R-Pola-Glo: Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP (clinicaltrials.gov) - P2 | N=125 | Active, not recruiting | Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting ➔ Active, not recruiting

Enrollment closed • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone for previously untreated diffuse large B-cell lymphoma: A real-world, multi-center, retrospective cohort study. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBL) (MK-2140-011/waveLINE-011) (clinicaltrials.gov) - P2 | N=594 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology